Product Description
Viloxazine is used to treat attention deficit hyperactivity disorder (ADHD). It belongs to the group of medicines called selective norepinephrine reuptake inhibitors (SNRIs). (Sourced from: https://www.mayoclinic.org/drugs-supplements/viloxazine-oral-route/side-effects/drg-20512960?p=1)
Mechanisms of Action: NRI Inhibitor,5-HT2B Antagonist,5-HT2C Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Ireland | Morocco | Pakistan | Peru | Portugal | Slovenia | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: Supernus
Company Location: ROCKVILLE MD 20850
Company CEO: Jack A. Khattar
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 812P310 | P3 |
Active, not recruiting |
Attention Deficit Disorder with Hyperactivity |
2026-09-01 |